COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

NCL News Archive

Monday, April 19, 2021

NCL's 2020 Annual Report

The NCL has recently published its 2020 Annual Report. The report highlights NCL's research activities in support of the program's four objectives:

Characterize nanomedicines using standardized methods Conduct structure activity relationship (SAR) studies Facilitate regulatory review of nanotech constructs Engage in educational and knowledge sharing efforts

In addition, the report... View Post


Friday, March 5, 2021

New Assay Cascade Awardees Announced - March 2021

The NCL solicits applications for the most promising cancer nanomedicine candidates for acceptance into its Assay Cascade characterization and testing program. Nanomedicines accepted into the program will undergo a rigorous evaluation that may include sterility and endotoxin testing, physicochemical characterization, in vitro hemato- and immunotoxicity, and in vivo studies to evaluate safety,... View Post


Wednesday, March 3, 2021

NCL Characterization Services & Resource Guides

The NCL has several new brochures that highlight the capabilities, services and resources available through the lab. The brochures are intended to provide developers and potential collaborators with a more in-depth perspective of the characterization typically condcuted on nanomedicines. 

NCL Services and Resource Guide: Introduces the expertise available at the NCL and outlines the... View Post


Thursday, February 11, 2021

Physicochemical Characterization Guides

Liposomes, colloidial metal nanoparticles, and polymeric/polymeric prodrug nanoparticles are among the most common nanotechnology platforms used in drug delivery. To assist developers working with these platforms, the NCL has created an overview of the most critical characterization parameters as well as the techniques most commonly employed. Each nanoformulation is unique; as such, these are... View Post


Monday, October 12, 2020

Submissions Open to COVID-19 Applications

The NCL is temporarily opening its Assay Cascade characterization program to nanotech concepts with a focus on COVID-19. Those interested in applying for a COVID-19 concept can complete the NCL White Paper application found on our website. Submissions deadlines will follow the same quarterly submissions for cancer concepts—March, June, September & December.

The next deadline for... View Post


Monday, October 5, 2020

Novel prodrug platform enables drug delivery to lymphatic system

Researchers at the NCL have developed a nanotechnology platform which targets the lymphatic system via scavenger receptor A1 (SR-A1), a cell surface receptor highly expressed on cells lining the vasculature and myeloid cells within lymph nodes. By targeting the lymphatics, this poly(L-lysine succinylated) (PLS) polymer could provide new treatment options for a variety of diseases including... View Post


Thursday, September 24, 2020

New Assay Cascade Awardees Announced - September 2020

The NCL solicits applications for the most promising cancer nanomedicine candidates for acceptance into its Assay Cascade characterization and testing program. Nanomedicines accepted into the program will undergo a rigorous evaluation that may include sterility and endotoxin testing, physicochemical characterization, in vitro hemato- and immunotoxicity, and in vivo studies to evaluate safety,... View Post


Tuesday, September 22, 2020

Next Application Deadline - March 1, 2021

The next deadline for application to NCL’s Assay Cascade characterization program is March 1, 2021. Visit our application and instructions page to download the template and review the evaluation criteria: https://ncl.cancer.gov/working-ncl/ncl-assay-cascade-application-process

Have questions about the application, evaluation criteria, or the overall process? Please... View Post


Friday, July 31, 2020

Nanotechnology—Over a Decade of Progress and Innovation

The US FDA released a report summarizing the agency's efforts in the field of nanotechnology. The report "Nanotechnology—Over a Decade of Progress and Innovation" can be accessed online here: https://www.fda.gov/media/140395/download. You can also watch Dr. Anil Patri, Chair of the FDA Nanotechnology Task Force, present on the topic August 13th. Details and registration for thew webinar are... View Post


Friday, July 31, 2020

Assay Cascade Awardees Announced - July 2020

The NCL solicits applications for the most promising cancer nanomedicine candidates for acceptance into its Assay Cascade characterization and testing program. Nanomedicines accepted into the program will undergo a rigorous evaluation that may include sterility and endotoxin testing, physicochemical characterization, in vitro hemato- and immunotoxicity, and in vivo studies to evaluate safety,... View Post


Pages